Improved Outcomes in Men with Advanced Prostate Cancer

The impressive and positive clinical trial results that are described by Fizazi et al. 1 and James et al. 2 in this issue of the Journal represent an important advance in androgen-signaling inhibition for metastatic prostate cancer. The LATITUDE and STAMPEDE research teams report encouraging improve...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 377; no. 4; pp. 388 - 390
Main Author Logothetis, Christopher J
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 27.07.2017
Subjects
Androgens
Cancer therapies
Chemotherapy
Endocrine therapy
Health risk assessment
Humans
Male
Mens health
Metastasis
Prostate cancer
Prostatic Neoplasms
Survival analysis
Online AccessGet full text

Cover

More Information
Summary:The impressive and positive clinical trial results that are described by Fizazi et al. 1 and James et al. 2 in this issue of the Journal represent an important advance in androgen-signaling inhibition for metastatic prostate cancer. The LATITUDE and STAMPEDE research teams report encouraging improvements in the initial treatment of men with advanced prostate cancer. Metastatic, castration-sensitive prostate cancer is diagnosed in a small proportion of men with prostate cancer at initial presentation and is disproportionately represented in lethal prostate cancer. The findings of these two trials suggest that therapeutically relevant biologic features of this form of cancer are shared with . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMe1704992